Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $38.98 -0.54%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -5.4%
Join SI Premium – FREE
Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva shares Phase 3 data on once-monthly schizophrenia injection
- XPeng Inc. (XPEV) call put ratio 2.7 calls to 1 put with a focus on October 14 calls
- Teva Pharma (TEVA) call put ratio 1.7 calls to 1 put as share price down 0.79%
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
